Press Releases

In This Section

Breadcrumb

Home // Investors // Press Releases //

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Novelion Therapeutics Observes World Lipodystrophy Day
VANCOUVER, British Columbia and CAMBRIDGE, Mass. , March 31, 2019 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ: NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, in association with its subsidiary Aegerion
View HTML
Toggle Summary Novelion Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results
Company achieves FY 2018 total net revenues of $130.4 million   FY 2018 operating expenses reduced by $27.2 million , or 18.4% VANCOUVER, British Columbia , and CAMBRIDGE, Mass. , March 14, 2019 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ: NVLN), a biopharmaceutical company dedicated to
View HTML
Toggle Summary Novelion Therapeutics Observes Rare Disease Day
Company Joins NORD, EURORDIS, CORD, The Global Genes Project and Others Worldwide in Supporting Awareness of Rare Diseases VANCOUVER, British Columbia and CAMBRIDGE, Mass. , Feb. 28, 2019 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ: NVLN), a biopharmaceutical company dedicated to
View HTML
Toggle Summary Novelion Therapeutics Subsidiary Enters Into Licensing Agreement for JUXTAPID® in Japan
Out-licensing of commercialization rights allows for significant operating expense savings Upfront payments improve near-term liquidity VANCOUVER, British Columbia , Feb. 06, 2019 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc.  (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new
View HTML
Toggle Summary Novelion Therapeutics Announces Leadership Change
Novelion General Counsel Benjamin Harshbarger Appointed as Interim Chief Executive Officer (CEO) VANCOUVER, British Columbia , Nov. 20, 2018 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc.  (NASDAQ:NVLN), today announced that General Counsel, Benjamin Harshbarger , has been appointed as interim CEO,
View HTML
Toggle Summary Novelion Therapeutics Reports Third Quarter 2018 Financial Results
VANCOUVER, British Columbia , Nov. 09, 2018 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ: NVLN), a biopharmaceutical company dedicated to developing and commercializing therapies for individuals living with rare diseases (“Novelion” or the “Company”), today reported financial results for
View HTML
Toggle Summary Novelion Therapeutics Subsidiary Enters Into Term Loan Agreement and Novelion Provides Business Update
- New Aegerion loan facility, provided by existing bondholders, strengthens balance sheet and is expected to provide bridge to a potential comprehensive long-term capital restructuring - Company expects to achieve positive cash flow at Aegerion level by 2Q 2019 on full-year net product sales of
View HTML
Toggle Summary Novelion Therapeutics Observes Familial Hypercholesterolemia Awareness Day
VANCOUVER, British Columbia and CAMBRIDGE, Mass. , Sept. 24, 2018 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ: NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, announced today its observance of The FH Foundation’s
View HTML
Toggle Summary Novelion Therapeutics Announces Next Phase of Operational Improvements
Once fully implemented, plans expected to reduce annual costs by approximately $35 million VANCOUVER, British Columbia , Aug. 23, 2018 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc.  (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with
View HTML
Toggle Summary Novelion Therapeutics Reports Second Quarter 2018 Financial Results
Following recent marketing approval in both generalized and partial lipodystrophy indications, European launch of MYALEPTA® has commenced VANCOUVER, British Columbia , Aug. 07, 2018 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ: NVLN), a biopharmaceutical company dedicated to developing
View HTML